FULC · CAMP 10-KMar 5 '26
“In exchange for the license rights, Fulcrum paid us a $0.4 million upfront payment.”
LLY · CAMP 10-KMar 5 '26
“During the years ended December 31, 2025 and 2024, we recorded $0.1 million and $0.5 million, respectively, as a reduction in R&D expense in the consolidated statement of operations and comprehensive loss as a result of the earned R&D reimbursement from Eli Lilly.”